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Abstract
Pancreatic cancer is estimated to surpass breast cancer to become the third leading cause
of cancer-related death in the USA in 2016. The 5-year overall survival is 7%, and most
individuals are diagnosed with advanced disease. Thus, there is a need to improve the
early detection of pancreatic cancer in order to detect and improve survival in the same
way that mammograms and colonoscopies have improved survival for individuals with
breast and colorectal cancer. This chapter discusses the genetics of hereditary pancreatic
cancer, the current available screening options, and the use of biomarkers for early
detection of pancreatic cancer.
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1. Introduction
Pancreatic  cancer  remains  a  deadly  disease  despite  decades  of  research  and  treatment
advances. In 2016 in the USA, it is estimated that pancreatic cancer will become the third
leading cause of cancer-related deaths with over 53,000 individuals diagnosed and over 41,000
deaths [1]. Only 9% of newly diagnosed pancreatic cancer is localized and the 5-year overall
survival is 7%, which lags behind other solid tumor malignancies [1]. It is estimated that by
the year 2030, pancreatic cancer will be the second leading cause of cancer death in the USA
[2]. Thus, due to most pancreatic cancers presenting at a later stage with poor overall survival,
early detection methods must be implemented to improve treatment outcomes. Pancreatic
cancer has been shown through several studies to have a hereditary disposition with estimates
ranging from 3 to 16% of newly diagnosed cases [3, 4]. There are several germline mutations
that have shown to be at risk for the development of pancreatic cancer, including BRCA1,
BRCA2, ATM, PALB2, CDKN2A, STK11, PRSS1, MEN1, MSH2, VHL, TP53, PALLD, EPCAM,
MLH1, MSH6, APC, and FANCC [5, 6].
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Currently, there are no guidelines for pancreatic cancer screening from the American Cancer
Society, National Comprehensive Cancer Network, and the US Preventative Task Force. The
International Cancer of the Pancreas Screening (CAPS) Consortium convened in 2011 to
examine the best available evidence regarding pancreatic cancer screening to provide guide-
lines [7]. This book chapter focuses on what constitutes hereditary pancreatic cancer and what
risk factors are associated with pancreatic cancer development. We also examine recent
literature discussing further methods of early detection of pancreatic cancer.
2. Familial pancreatic cancer genetics
Estimates vary in the literature, but it is recognized that approximately 3–16% of cases of
pancreatic cancer have a hereditary component [3, 4, 8, 9]. What constitutes the definition of
hereditary pancreatic cancer also varies between known germline mutations with associations
with pancreatic cancer to a family history of pancreatic cancer. In individuals with a family
history of pancreatic cancer, the risk increases several fold with each first-degree relative
(sibling, child, or parent) who is affected. In families with pancreatic cancer, one first-degree
relative with pancreatic cancer increased risk by twofold. This risk was increased to nearly
threefold if the individual was diagnosed before the age of 60 years [10]. A National Familial
Pancreas Tumour Registry (NFPTR) study indicated that the risk of pancreatic cancer increased
to 57-fold with three or more affected family members with pancreas cancer [8]. Typically,
individuals with hereditary pancreatic cancer also are diagnosed at younger ages (<50 year)
compared with those with sporadic pancreatic cancer, which occurs at 61 years of age and
older [11]. Also of note is that tobacco use can lead to an increased risk of pancreatic cancer in
those individuals at risk due to hereditary pancreatic cancer [11].
There are several genetic syndromes that are related to an increased risk of pancreatic cancer
and are summarized in Table 1. Hereditary breast and ovarian cancer (HBOC) is associated
by germline mutations of BRCA1 and BRCA2 [12]. These same mutations also carry a
significant risk for the development of pancreatic cancer, with the relative risk varying by at
lead two to threefold in those individuals with BRCA1 and BRCA2 mutations [13, 14]. The
BRCA1 gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic
stability and also acts as a tumor suppressor. The protein is associated with the BRCA1
associated genome surveillance complex (BASC) along with RNA polymerase II with the
histone deacetlylase complexes. The protein plays a role in transcription along with DNA
repair of double-strand breaks and recombination [15]. BRCA2 encodes for a protein that is
also associated with double-strand break repair and homologous recombination. It is also
associated with multiple proteins, including RAD51 and PALB2 [16]. PALB2 (partner and
localizer of BRCA2) has also recently been recognized as a significant germline mutation
associated with HBOC and involved in the development for pancreatic cancer [17]. The roles
of these mutations in the pathogenesis of pancreatic cancer has not always been clear in
preclinical animal models, but it is agreed that they contribute to defective DNA repair that
leads to accumulation of damaged DNA and genomic instability that would lead to pancreatic
cancer development [18].
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Syndrome Gene (s) involved Clinical features
Hereditary breast and
ovarian cancer (HBOC)
BRCA1, BRCA2,
PALB2
Breast cancer, ovarian cancer, male breast cancer, uveal melanoma,
stomach cancer, biliary cancer, endometrial cancer.
Ataxia-telangiectasia ATM Cerebellar ataxia, telangiectasia of the conjunctiva and skin,
immunodeficiency, leukemia.
Lynch MLH1, MSH2,
MSH6, PMS2
Colorectal cancer, endometrial cancer, ovarian cancer, stomach
cancer, small bowel cancer, transitional cell cancer, glioma, and
sebaceous neoplasms.
Peut-Jeghers (PJS) STK11 Mucocutaneous pigmentation, hamartomatous polyps; colorectal,
stomach, small bowel, testicular, breast, cervical, and ovarian cancer
Familial adenomatous
polyposis (FAP)
APC, MUTYH Colorectal cancer, desmoid tumors, medulloblastomas, osteomas,
fibromas, supernumerary teeth, gastric polyps
Familial atypical mole
and multiple melanoma
(FAMMM)
CDNK2A Melanoma, CNS malignancies, Acute Lymphoblastic leukemia.
Familial pancreatitis PRSS1, CFTR,
SPINK1, CASR,
CTRC, CPA1
Pancreatitis, cystic fibrosis, diabetes
Li-Fraumeni TP53 Sarcomas, breast cancer, Gliomas, Choroid plexus carcinomas, and
adrenocortical carcinomas
Fanconi’s anemia FANCC, FANCG Aplastic anemia, bone marrow failure, acute myeloid leukemia,
myelodysplatic syndrome
Table 1. Inherited syndromes associated with increased risk of pancreatic cancer.
Other DNA repair mechanism-based genes implicated in familial pancreatic cancer include
the gene ATM, whose product works with several proteins involved in DNA damage and
subsequently the cell cycle [19]. The gene ATM is more commonly known in relation to Ataxia-
telangiectasia which is manifested by progressive cerebellar ataxia, oculomotor apraxia,
telangiectasia of the conjunctiva and skin, immunodeficiency, sensitivity to ionizing radiation,
and an increase rate of malignancies such as leukemia. In one series of 166 familial pancreatic
cancer probands, 2.4% carried deleterious mutations [19]. Lynch syndrome, which is an
autosomal dominant disorder caused by a germline mutation in one of either MLH1, MSH2,
MSH6, or PMS2. The genes MLH1, MSH2, MSH6, and PMS2 function as DNA mismatch repair
genes. Lynch syndrome can also occur because of loss of expression of MSH2 due to deletion
in the EPCAM gene [20]. Typical affected family members of lynch have an increased risk of
colon cancer but are at risk for several other malignancies, including pancreatic cancer [21].
The risk of pancreatic cancer in families with Lynch syndrome has been reported to be as high
as an 8.6-fold increase with a cumulative risk of 3.7% by age of 70 years [22]. Another familial
syndrome associated with colon cancer is familial adenomatous polyposis (FAP). This also
follows an autosomal dominant pattern of inheritance in the APC gene. APC is a tumor
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suppressor gene that is involved in the Wnt signaling pathway along with pathways associated
with migration and adhesion, transcription, and apoptosis. Pancreatic cancer has been
reported to have a relative risk of 4.46 in families with familial adenomatous polyposis [23]. A
variant of FAP, attenuated familial adenomatous polyposis (AFAP) is characterized by
mutations in the MUTYH gene [24]. To date there is no reported linkage with this gene with
pancreatic cancer development although due to its involvement in DNA damage repair an
association with pancreatic cancer risk may be discovered.
Peutz-Jegher syndrome (PJS) is another autosomal dominant syndrome that leads to risks in
several malignancies. It is characterized clinically by multiple hamartomatous polyps in the
gastrointestinal tract and mucocutaneous pigmentation. Individuals with PJS are affected by
mutations in STK11 gene which is a serine threonine kinase tumor suppressor gene. Colon,
stomach, small bowel, ovarian, breast, cervical, and testicular cancer risk is increased, as is
pancreatic cancer The risk of pancreatic cancer in some studies has indicated as high as a 26%
risk in those with STK11 mutations for pancreatic cancer development by the age of 70 with a
relative risk of 76 [25].
Familial atypical mole and multiple melanoma (FAMMM) syndrome is yet another autosomal
dominant disorder that is characterized by family members with multiple nevi along with
cutaneous and ocular melanomas. This disorder involves mutations in the p16 gene or CDNK2
gene which also can lead to pancreatic cancer. The risk of pancreatic cancer development by
the age of 75 has been reported to be between 17 and 25% [26, 27]. In some studies, there has
been reported to be a 13- to 22-fold increase of pancreatic cancer [27]. CDKN2A is a tumor
suppressor involved in inducing cell cycle arrest in the G1 and G2 phase. What is interesting
about the CDKN2A gene is that somatic mutations or other alterations occur in 90% of
individuals with pancreatic cancer making it an important step in tumor promotion in
pancreatic cancer [28].
Chronic or recurrent acute pancreatitis also has a hereditary component that has become
associated with pancreatic cancer development [29]. In families with hereditary pancreatitis,
the risk for pancreatic cancer increases substantially past the age of 50, with the risk being 10%
by the age of 50, increasing to 19% by the age of 60, and then to 54% by the age of 75 years in
one study [30]. In individuals who smoke with hereditary pancreatitis, the risk of pancreatic
cancer increase by twofold if they are current or former smokers and pancreatic cancer in these
individuals occurs 20 years earlier [31]. The genetics of hereditary pancreatitis is complex.
Germline mutations in the serine protease 1 gene (PRSS1) follows an autosomal dominant
pattern for hereditary pancreatitis. The gene function of this enzyme functions as a protectant
against trypsin. Trypsin is a digestive enzyme secreted by the pancreas into the duodenum
and control of its activity is through several proteins including PRSS1, serine protease inhibitor
Kazal 1 (SPINK1), cystic fibrosis transmembrane conductance regulator (CFTR), chymotryp-
sinogen C (CTRC), and calcium-sensing receptor (CASR) [32]. The repeated exposure of
trypsin and resulting pancreatitis has been shown preclinically to induce pancreatic fibrosis
and inflammation [33]. Biallelic alterations in the aforementioned gene SPINK1, leads to an
autosomal recessive pattern of chronic pancreatitis [34]. SPINK1 encodes a pancreatic secretory
trypsin inhibitor and is regulated as an acute phase reactant being expressed during the
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inflammatory process acting as a feedback inhibitor in trypsin [34]. CFTR follows an even more
complex genetic pattern with regards to hereditary pancreatitis [35]. CFTR functions as an ion
channel involved in the transport of chloride and thiocyanate and is associated with cystic
fibrosis, a condition manifested by pancreatic insufficiency, failure to thrive, sinus disease, and
respiratory disease [36]. Homozygotes mutations of the CFTR gene lead to severe chronic
pancreatitis but compound heterozygote mutations may also lead to chronic pancreatitis [37].
Homozygous mutations carry a risk of 40–80-fold for chronic pancreatitis over the general
population [37]. Individuals who carry only one allelic mutation of the CFTR gene still are at
an increased risk of chronic pancreatitis three- to fourfold over the general population. Those
individuals with heterozygous CFTR mutations typically have coexisting germline mutations
in either SPINK1 or CTRC [38]. The CTRC gene carries a risk for chronic pancreatitis but usually
in conjunction in individuals with mutations in either CFTR or SPINK1 [39]. CTRC encodes
the enzyme Chymotrypsin C that helps degrades trypsin. Other genes associated with
recurrent acute and chronic pancreatitis have also been discovered. CLDN2 encodes a protein
that function in tight junction and is involved in ion and water transportation. Mutations in
this gene have been associated with chronic pancreatitis particularly in those individuals who
consume alcohol. It has recently been described to be involved in pancreatic acinar cells [40].
And finally, the gene CPA1 encodes a pancreatic digestive enzyme whose mutations have been
found to be involved in early onset of chronic pancreatitis. The mutation appears to be involved
in endoplasmic reticulum stress as opposed to direct trypsin activity in regards to the devel-
opment of chronic pancreatitis [41].
There are other syndromes that do not have nearly as strong evidence as the aforementioned
syndromes for pancreatic cancer risk, but studies have indicated there are associations. Li-
Fraumeni syndrome is an autosomal dominant disorder that is a result of germline mutations
in the tumor protein p53 gene (TP53) [42]. TP53 is a tumor suppressor gene that has a major
role in regulating the cell cycle in response to DNA damage. In its absence, cells containing
damaged DNA survive and proliferate leading to malignant transformation. Typical malig-
nancies at risk with germline mutations in TP53 include osteosarcomas, rhabdomyosarcomas,
breast cancer, gliomas, and adrenocortical carcinomas [42]. However, in a study of 24 families
with confirmed TP53 germline mutations, the risk of pancreatic cancer was 7.3-fold compared
to the general population [43]. Fanconi anemia is an autosomal recessive or X-linked disorder
that results in congenital malformations along with pancytopenia and macrocytic anemia and
is characterized by germline mutations in the FANC family of genes [44]. These groups of genes
are involved in DNA repair and interact with the BRCA pathway. Mutations in the FANCC
and FANCG genes have been reported in families that have developed young onset (less than
55 years of age) pancreatic cancer [45, 46].
As genetic sequencing become more cost effective for the greater population there will likely
be more genes discovered in relation to the risk of pancreatic cancer. Traditional sequencing
of gene discovery may uncover additional germline mutations along with single nucleotide
poylmorphisms (SNPs). Epigenetic sequencing analysis may also unveil methylated promot-
ers that place an individual at risk for the development of pancreatic cancer. An example of
whole genomic sequencing identifying new risks in the human genome came from a study
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examining over 1890 individuals with pancreatic cancer and compared with 2654 controls that
showed an association between a locus on 9q34 and pancreatic cancer through the SNP
rs505922 [47]. This SNP maps to the first intron of the ABO blood group gene which leads
credence to prior epidemiologic evidence suggesting that individuals with blood group O may
have a lower risk of pancreatic cancer than those with groups A or B [47].
3. Other risk factors for pancreatic cancer development
Other risk factors exist for the development of pancreatic cancer and may be associated with
changes in the human genome based upon enhanced environmental susceptibility with
specific germline alterations. What is currently known is that obesity plays a risk for the
development of pancreatic cancer. Two longitudinal US cohort studies, the Health Professio-
nals Follow-up study and the Nurses’ Health Study, had decades of follow-up through
questionnaires which examined the risk of Body Mass Index (BMI), height, and level of
physical activity. Individuals with a BMI of at least 30 kg/m2 had an elevated risk of pancreatic
cancer compared with those with a BMI less than 23 kg/m2 with a relative risk of 1.72. Height
was also associated with an increased pancreatic cancer risk of 1.81 RR when comparing the
tallest category (equal to or greater than 185.4 cm in men, greater than 167.6 cm in women) to
the shortest category (less than or equal to 172.7 cm in men, less than 157.5 cm in women). In
individuals with moderate physical activity defined as equal to or greater than 11.0 MET hours
per week in men and equal to or greater than 10.8 MET hours per week in women, the risk of
pancreatic cancer was reduced by 59% in men and 48% in women [48]. The “Western” dietary
pattern of high intake of saturated fats and smoked or processed meats has also been shown
to influence the risk of pancreatic cancer development. In a 7-year prospective study, those that
had the highest quintile of intake of processed meat had a 68% increased risk compared with
those in the lowest quintile. Higher intake pork and red meat compared with the lowest
quintiles were also associated with a 50% risk of pancreatic cancer [49]. A meta-analysis of 11
prospective studies published in 2012 confirmed that processed meat consumption was
associated with an increased risk of pancreatic cancer in men but not in women. The relative
risk in men was 1.29 [50]. Other social risk factors that are modifiable include tobacco use and
alcohol use, particularly heavy alcohol use since it contributes to the development of pancrea-
titis. Heavy alcohol use is defined as having at least nine drinks per day [51]. Tobacco use leads
to a 2.2-fold increased risk of developing pancreatic cancer and cessation must take place for
20 years prior to returning to the risk of nonsmokers [52]. Of note is that exposure of second-
hand smoke confers an odds ratio of 1.21 relative to those individuals with no exposure [53].
The risk increases in active smokers by cigarette pack-years.
Diabetes has been recognized more and more as a tremendous risk factor for pancreatic cancer
development. Due to one of the functions of the pancreas in regulating glucose metabolism,
diabetes is a common presenting finding for pancreatic cancer. In one dose-response meta-
analysis of prospective observational studies, it was shown that every 0.56 mmol/L increase in
fasting blood glucose is associated with a 14% increase in the rate of pancreatic cancer [54].
This roughly translates to around a 0.35% change in the Hemoglobin A1C (HgbA1C). In
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another meta-analysis examining 44 studies of diabetes and pancreatic cancer risk, the duration
of diabetes was associated with increased risk. For individuals with longer duration of
diabetes, the relative risk slowly decreased, with RR being 1.64 for having diabetes for at least
2 years, then RR of 1.58 for diabetes at least five years, and 1.50 RR for having diabetes for at
least 10 years [55]. In a nested case-control study within the Health Improvement Network in
the UK, new onset of type 2 diabetes was associated with an estimate odds ratio (OR) of 2.16
of pancreatic cancer [56].
Other environmental risk factors include Hepatitis B virus infection and Helicobacter pylori
infection. Both have been seen in studies and likely warrant further analysis. In a meta-analysis
of nine studies involving 3033 patients, the risk of H. pylori infection was associated with an
OR of 1.47 of developing pancreatic cancer. When broken down into regions such as East Asia
the OR goes up to 2.01, but in North America it is 1.17 [57]. The association of hepatitis B virus
has also been seen albeit in a single institution study of 476 pancreatic cancer patients and 879
healthy controls. The adjusted odds ratio (AOR) of hepatitis B exposure and pancreatic cancer
was 2.5 in anti-Hepatitis B core antigen positive (HBc) patients, 2.3 in anti-HBc positive/anti-
Hepatitis B surface antigen (HBsAg) positive patients, and the AOR was 4 for anti-HBc
positive/antiHBs negative patients [58]. A cohort of over 66,000 men and women were followed
in the Vitamins and Lifestyle study from 2000 to 2008. During follow up, 151 individuals
developed pancreatic cancer. Magnesium intake was studied, and for every 100 mg/day
decrement in magnesium intake, there was a 24% increase in the incidence of pancreatic cancer
through multi-variate analysis that included age, gender, body mass index, and nonsteroidal
anti-inflammatory drug (NSAID) use. Thus, magnesium intake may be beneficial for primary
prevention of pancreatic cancer [59]. The etiology of why magnesium would be protective for
pancreatic cancer is not completely clear. There have been associations with magnesium and
the improvement in insulin sensitivity. Deficiency in magnesium may also be associated with
free radical formation that leads to DNA damage and cancer development [60], and magne-
sium may act as a scavenger of harmful chemicals [61].
The microbiome is a burgeoning field involving the study of the microbial flora in humans and
its effect on health. Human flora in the mucocutaneous surfaces are composed of a variety of
aerobic and anaerobic bacteria. The human microbiome is altered by several environmental
factors along with host hygiene such as alcohol use, periodontitis, and the use of antibiotics.
The microbiome may play a greater role in inflammation and the eventual development of
several malignancies, including pancreatic cancer [62]. A study examining the microbiome by
oral wash samples from 361 individuals who developed pancreatic cancer and comparing it
to 371 matched controls showed the presence of two species of bacteria, Porphyromonas
gingivalis and Aggregatibacter actinomycetemcomitans associated with an increased risk of
pancreatic cancer [63]. The presence of P. gingivalis in oral wash samples was associated with
a 59% increased risk for pancreatic cancer and the presence of A. actinomycetemcomitans was
associated with a 119% increased risk. These findings do not establish a true causal link but
are intriguing and warrant greater investigation as influencing the microbiome may have a
dramatic in pancreatic cancer prevention.
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4. Methods of early detection of pancreatic cancer
Because pancreatic cancer carries a poor prognosis, identifying those individuals at risk for
developing it is vital due to a phenomenon called anticipation. Anticipation in genetics is
defined as when a genetic disorder is passed on the next generation, the symptoms of the
genetic disorder become apparent at an earlier age. This is true in several familial forms of
cancer such as breast or colorectal and influences when an individual is recommend screening
modalities such as mammogram or colonoscopy. In a large study examining 1223 individuals
from 106 families with familial pancreatic cancer, anticipation was noted. For individuals
affected with pancreatic cancer, the median age of death from pancreatic cancer was 70 years
old in generation one, 64 years old in generation two, and 49 years old in generation three [64].
In 2010, the International Cancer of the Pancreas Screening (CAPS) consortium was formed to
help organize global pancreatic screening [7]. The consortium was composed of 50 experts
from 10 countries in the fields of epidemiology, genetics, gastroenterology, radiology, oncology,
surgery, and pathology. This group was composed of physicians, research scientists, and
genetic counselors from a wide variety of practice settings including community-based
practices and academic centers. The consensus on who should be offered screening was based
upon best available evidence. For individuals with three or more blood relatives with pancre-
atic cancer, with at least one affected first-degree relative (FDR) should be considered for
screening. FDR denotes either a parent, brother, sister, or child. Those with at least two affected
FDRs should be considered for screening. And finally those with two affected blood relatives
with pancreatic cancer with at least one FDR should be considered. For those individuals with
only a young onset pancreatic cancer relative (not an FDR), there was no consensus reached
on offering screening. In regards to mutation carriers, those with Peutz-Jeghers regardless of
family history should be considered for screening. For BRCA2 mutation carriers with one or
more affected FDR with pancreatic cancer and those with two or more affected family members
(even without a FDR) should be considered for screening. For PALB2 mutation carriers with
one or more affected FDR should be considered for screening. For individuals with p16
germline mutations with one or more affected FDR with pancreatic cancer should be consid-
ered for screening. For individuals with Lynch syndrome with one or more affected FDR with
pancreatic cancer should be considered for screening. The age to initiate screening was not
agreed upon nor the age to end screening. The consensus regarding screening modalities was
utilizing endoscopic ultrasound (EUS) and magnetic resonance imaging (MRI)/magnetic
resonance cholangiopancreatography (MRCP) [7]. Computed tomography (CT) of the
abdomen has the disadvantage of utilizing radiation as opposed to MRI/MRCP’s reliance of
magnetic fields. Furthermore, in a screening program utilizing either CT, MRI, or EUS, CT
scans were inferior in detecting pancreatic lesions. CT scans detected pancreatic abnormalities
in 11% of the individuals compared with 33.3% for MRI and 42.6% for EUS [65]. As always,
the risks of these modalities must be considered, particularly with EUS. Regarding the routine
follow up per the CAPS consortium, a 12-month interval was recommended but no consensus
on what tests to repeat. Surgical intervention for pancreatic lesions was also recommended to
be considered after multidisciplinary assessment, preferably within research studies [7].
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There are a handful of published studies on screening for pancreatic cancer. One study
published in 2010 from Columbia University Medical Center/NewYork Presbyterian Hospital
utilized a screening program similar to the recommendations put forth from the CAPS
consortium. In this study, individuals with a family history of pancreatic cancer were allowed
to enroll in a prospective screening study and were placed into three risk groups: average,
moderate, or high risk. The individuals in average risk were those with one family member
with pancreas cancer diagnosed over the age of 55 years old. Individuals with moderate risk
were defined as those with two first-, second-, or third-degree relatives with pancreatic cancer
or those with one first-degree relative with pancreatic cancer less than 55 years of age. A
second-degree relative denotes an aunt, uncle, grandparent, grandchild, niece, nephew, or half-
brother or half-sister. A third-degree relative denotes a great grandparent, great grandchildren,
and first cousins. Individuals were defined as high risk for pancreatic cancer if there were three
or more first-, second-, or third-degree relatives with pancreatic cancer; two or more first-
degree relatives with pancreatic cancer; one first-degree relative and one second-degree
relative if one was diagnosed at 55 years or younger, and any genetic syndrome associated
with pancreatic cancer such as BRCA, Peutz-Jeghers Syndrome, Lynch, Familial Melanoma, or
hereditary pancreatitis. Depending upon the individual’s risk, they were offered basic blood
testing (average risk) or blood testing with MRI (moderate risk) or blood testing, EUS, and
MRI (high risk). In these asymptomatic individuals, pancreatic cancer was detected in two of
them- one resectable and one stage IV pancreatic cancer. Four patients has intraductal
mucinous neoplasms (IPMN) lesions, two individuals were diagnosed with ovarian cancer,
one individual with retroperitoneal carcinoid, and one with papillary carcinoma of the
thyroid [4]. All told, 18% of the 51 asymptomatic individuals in the program were found to
have a preneoplastic or neoplastic lesion. In a follow-up report on their website, 7 of the 29
individuals that have continued screening have also been found to have abnormalities of the
pancreas [66]. In another study enrolling 411 asymptomatic individuals performed through a
multi-institutional collaboration in Europe, surveillance was offered through individuals at
risk for pancreatic cancer [67]. Individuals with a confirmed CDKN2A mutation or with a
personal history of melanoma and a known mutation in the family were eligible along with
individuals from families with two or three first-degree relative with pancreatic cancer. All
individuals were offered MRI/MRCP along with EUS every third year of screening. For
individuals with CDNK2A mutations, 13 (7.3%) developed pancreatic cancer. The resection
rate in those individuals was 75% and the 5-year survival was 24%. In the familial pancreatic
cancer cohort, 13 individuals (6.1%) underwent a surgical resection, but only four had high-
risk lesions. In a cohort of 10 individuals with BRCA1/2 or PALB2 mutation, one individual
(3.8%) developed pancreatic cancer [67]. Various screening studies have been published
throughout the past several years examining several at risk-populations. Routine screening for
pancreatic cancer in all healthy individuals currently is not recommended.
Biomarkers for pancreatic cancer continue to be developed. As mentioned previously, the
occurrence of diabetes typically precedes pancreatic cancer and bears monitoring in those
individuals at risk for pancreatic cancer development. Carbohydrate antigen aka cancer
antigen 19–9 (CA 19–9) is the most common pancreatic cancer serum biomarker. However, this
biomarker’s sensitivity and specificity are not high as several benign conditions involving the
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gastro-biliary system can cause its elevation [68]. Furthermore, in individuals with negative
Lewis phenotype, the CA 19–9 is not elevated, even in the setting of widely metastatic
pancreatic cancer. Therefore, the development of newer biomarkers is of interest for pancreatic
cancer and those at risk for developing it. A study originating from MD Anderson and Dr.
Raghu Kalluri’s lab looked at exosomes, which are lipid-bilayer-enclosed extracellular vesicles
that contain protein and nucleic acids. The identification of cell surface proteoglycan, glypi-
can-1 (GPC1) is specifically enriched in cancer cells, particularly pancreatic cancer. The assay
itself simply uses a small amount of peripheral blood. In comparing individuals without cancer
and those with pancreatic cancer, the expression of GPC1 was always elevated in individuals
with pancreatic cancer. In a study examining the GPC1 levels in response to surgical resection
of pancreatic cancer, individuals who had a greater decrease of detectable GPC1 levels than
those that did not correlated to an improved overall survival [69]. Thus, GPC1 may be a
biomarker of interest for individuals at risk for pancreatic cancer. Another study identified
elevated plasma levels of branched-chain amino acids (BCAAs) are associated with an
increased risk of future pancreatic cancer diagnosis. The study examined cases of pancreatic
cancer with matched controls from four prospective cohort studies with blood collected at least
2 years before cancer diagnosis with the median time between blood collection and pancreatic
cancer diagnosis being 8.7 years. Several metabolites were analysed, and the BCAAs isoleucine,
leucine, and valine stood out as an increased risk of greater than twofold for pancreatic cancer
development [70]. Circulating BCAAs are elevated in obese individuals and those with insulin
resistance [71]. These findings also suggest that muscle protein loss happens much earlier than
anticipated in pancreatic cancer, thus contributing further to the debilitating nature of this
cancer. Other noninvasive serum approaches include the use of circulating tumor DNA
(ctDNA). In a study of patients who underwent resection of their primary pancreatic tumor,
the detection of ctDNA preceded the presence of measurable recurrent pancreatic cancer on
CT by 9.9 months [72]. Other clinical studies have examined the use of urinary KRAS in
advanced cancers requiring very small copy numbers of the KRAS ctDNA [73]. The implica-
tions of this and other work suggests that noninvasive testing is improving for detecting
pancreatic cancer and may be a consideration for clinical trial design in cohorts of those
individuals at risk of the developing pancreatic cancer.
5. Future directions
Pancreatic cancer remains a difficult cancer to diagnose and treat. The identification of
individuals who are at risk for pancreatic cancer is important for several reasons. The first
significant benefit is for the individual to be aware of their risk and to undergo a surveillance
program for the early detection of pancreatic cancer. This program should be compromised of
multi-disciplinary panel composed of oncologists, gastroenterologists, radiologists, patholo-
gists, and genetic counsellors. The benefit of early detection for an individual at high risk is
for improved survival for pancreatic cancer. Through remarkable work from Johns Hopkins
and Dr. Christine Iacobuzio-Donahue’s lab from autopsy series, pancreatic cancer appears to
take about 20 years from the first mutated cell to clinical presentation and metastasis [74]. This
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provides a window of opportunity in regards to early detection of the disease and a chance to
change the natural course of pancreatic cancer in an individual. The other benefits lie in
identifying individuals at risk for pancreatic cancer development and offering these individ-
uals opportunities to participate in clinical trials examining biomarkers—through either
serum, urine, or imaging or a combination. The improvement in the overall 5-year survival in
breast cancer was not born out of improved treatment for metastatic breast cancer, but through
the use of mammography, increased awareness of the cancer, and optimal management of
localized disease through a multi-modality approach. In an editorial by Hait and Levine, they
argued that the main focus by oncologists has been in treating tumors that are genetically
complex [75]. Their argument focuses on examining premalignant lesions and the likelihood
of dealing with less genetically complex lesions with treatment. One example of this approach
is the use of imatinib, a Bcr-abl inhibitor that is incredibly effective against chronic myeloge-
nous leukemia (CML). The effectiveness of this drug is measured by complete haematological
response (CHR). During the chronic phase of CML where the cancer genome is relatively
simple, the CHR is 95% for imatinib. As the tumor becomes more genetically complex through
disease progression of accelerated phase and then myeloid blast crisis, the CHR falls to 38%
and 7%, respectively [75]. This is what oncologists deal with pancreatic cancer, a cancer that
has likely metastasized by the time of clinical presentation, hence the low response rates of
current therapies.
The oppurtunity to detect pancreatic cancer early through better assays may also allow for
intervention. For instance, an individual without confirmed histological confirmation by way
of EUS with an elevated biomarker that is highly sensitive and specific to pancreatic cancer
may consider watchful waiting or treatment. The treatment may include agents such as
metformin, a biguanide which reduces weight and decreases fasting plasma insulin concen-
trations by enhancing insulin sensitivity via activation of 5ʹ-AMP-activated protein kinase
(AMPK) [76]. Metformin has also shown benefit in preclinical models in pancreatic cancer [77].
In a study of individuals who underwent resection for pancreatic cancer, metformin use was
associated with an improved survival [78]. The use of immunotherapeutic agents that have so
far been met with disappointment in treating advanced pancreatic cancer, may have signifi-
cantly improved outcomes in premalignant or early pancreatic cancer. Another example of
early intervention may be through the use of RANK ligand inhibitors that are available
commercially such as Denosumab (Xgeva, Prolia). In a three-dimensional organoid breast
cancer model from women that have BRCA1 mutation and pre-neoplastic legions, the inhibi-
tion of RANKL substantially curtailed tumorogenesis [79]. The possibility of offering a drug
like Denosumab which is administered subcutaneously and has relative few side effects as
opposed to offering a women with BRCA1 mutation risk reducing mastectomy or bilateral
oophorectomy particularly at a young age would likely be appealing for most individuals.
Costs of screening protocols in individuals at risk for pancreatic cancer development have been
examined and appears to be cost-effective [80]. Utilizing early detection programs through
several institutions may define better the risk factors for pancreatic cancer along with initiating
clinical trials for earlier intervention. The potential benefits of identifying and improving
survival in individuals with pancreatic cancer is tremendous. By examining those at high risk
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for developing the disease, the possibility of developing a more widespread early detection
tool for pancreatic cancer in the vein as mammograms may save countless lives in the future.
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